Michael Demurjian Sells 20,000 Shares of Tyme Technologies Inc (NASDAQ:TYME) Stock

Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of Tyme Technologies stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $0.97, for a total transaction of $19,400.00. Following the transaction, the insider now directly owns 24,005,617 shares in the company, valued at approximately $23,285,448.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Friday, March 20th, Michael Demurjian sold 7,071 shares of Tyme Technologies stock. The shares were sold at an average price of $1.03, for a total transaction of $7,283.13.
  • On Monday, March 16th, Michael Demurjian sold 4,904 shares of Tyme Technologies stock. The shares were sold at an average price of $1.03, for a total transaction of $5,051.12.
  • On Monday, February 10th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.34, for a total transaction of $26,800.00.
  • On Monday, January 27th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.52, for a total transaction of $30,400.00.
  • On Tuesday, January 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.90, for a total transaction of $38,000.00.
  • On Monday, January 13th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.64, for a total transaction of $32,800.00.
  • On Monday, January 6th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.47, for a total transaction of $29,400.00.
  • On Monday, December 30th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.07, for a total transaction of $21,400.00.

TYME stock opened at $1.10 on Thursday. Tyme Technologies Inc has a one year low of $0.86 and a one year high of $2.10. The company’s fifty day moving average price is $1.19 and its 200-day moving average price is $1.31. The company has a market capitalization of $132.67 million, a PE ratio of -4.58 and a beta of 0.54.

Tyme Technologies (NASDAQ:TYME) last released its earnings results on Wednesday, February 5th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. As a group, equities analysts expect that Tyme Technologies Inc will post -0.22 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC purchased a new position in shares of Tyme Technologies in the third quarter worth $71,000. Barclays PLC lifted its holdings in shares of Tyme Technologies by 102.1% in the fourth quarter. Barclays PLC now owns 59,040 shares of the company’s stock worth $83,000 after buying an additional 29,821 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Tyme Technologies by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 743,190 shares of the company’s stock worth $1,040,000 after buying an additional 18,481 shares in the last quarter. UBS Group AG lifted its holdings in shares of Tyme Technologies by 49.1% in the fourth quarter. UBS Group AG now owns 90,630 shares of the company’s stock worth $127,000 after buying an additional 29,829 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Tyme Technologies by 31.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 42,232 shares of the company’s stock worth $59,000 after buying an additional 10,124 shares in the last quarter. 11.76% of the stock is currently owned by hedge funds and other institutional investors.

TYME has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $9.50 price target on shares of Tyme Technologies in a report on Thursday, February 6th. Zacks Investment Research raised shares of Tyme Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, March 18th.

About Tyme Technologies

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Featured Article: How to use beta for portfolio diversification

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.